Compare BridgeBio Pharma Inc (BBIO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Raymond James Financial, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Raymond James Financial, Inc. trades at $179.97 (market cap $33.96B). The key difference: Raymond James Financial, Inc. is far larger — about 2× BridgeBio Pharma Inc's market cap, and Raymond James Financial, Inc. pays a 1.22% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RJF | |
|---|---|---|
Market Cap | $16.61B | $33.96B |
Sector | Health | Financials |
52-Week High | $90.17 | $180.55 |
52-Week Low | $47.29 | $140.89 |
Enterprise Value | $18.16B | — |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Raymond James Financial (RJF) trades at $176.56, down 1.54% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. Revenue and net income have grown steadily, with Q3 2026 reaching record revenues of $3.93 billion, up 16% year-over-year. The stock is supported by positive analyst sentiment and a consensus price target of $183.75.
The outlook for RJF is positive, driven by earnings growth and strategic acquisitions, though risks include market volatility and competitive pressures. With no sell ratings and a dividend payout, the stock presents a stable opportunity for investors seeking exposure to financial services, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
